Lutetium (177 Lu) oxodotreotide
- Status:
- Red
- Decision Date:
- September 2018
Comments
RED1,2,3: NICE TA539 - treating unresectable or metastatic neuroendocrine tumours. (Decision date - September 2018)
To be used in line with NHSE commissioning intentions.
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again